UniprotID	Q7Z2W4-3
Accession	Q7Z2W4;A4D1R2;A4D1S4;Q8IW57;Q8TAJ3;Q96N79;Q9H8R9;Q9P0Y7
EntryName	ZCCHV_HUMAN
ProteinName	Zinc finger CCCH-type antiviral protein 1 (ADP-ribosyltransferase diphtheria toxin-like 13) (ARTD13) (Inactive Poly [ADP-ribose] polymerase 13) (PARP13) (Zinc finger CCCH domain-containing protein 2) (Zinc finger antiviral protein) (ZAP)
GeneName	ZC3HAV1 ZC3HDC2 PRO1677
Length	624
Function	Antiviral protein which inhibits the replication of viruses by recruiting the cellular RNA degradation machineries to degrade the viral mRNAs. Binds to a ZAP-responsive element (ZRE) present in the target viral mRNA, recruits cellular poly(A)-specific ribonuclease PARN to remove the poly(A) tail, and the 3'-5' exoribonuclease complex exosome to degrade the RNA body from the 3'-end. It also recruits the decapping complex DCP1-DCP2 through RNA helicase p72 (DDX17) to remove the cap structure of the viral mRNA to initiate its degradation from the 5'-end. Its target viruses belong to families which include retroviridae: human immunodeficiency virus type 1 (HIV-1), moloney and murine leukemia virus (MoMLV) and xenotropic MuLV-related virus (XMRV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), togaviridae: sindbis virus (SINV) and Ross river virus (RRV). Specifically targets the multiply spliced but not unspliced or singly spliced HIV-1 mRNAs for degradation. Isoform 1 is a more potent viral inhibitor than isoform 2. Isoform 2 acts as a positive regulator of RIGI signaling resulting in activation of the downstream effector IRF3 leading to the expression of type I IFNs and IFN stimulated genes (ISGs).
Subcellular Location	Cytoplasm; Nucleus; Cytoplasm
Disorder	
ExposeBuried	
SurfaceAccessbility	
SecondStructure	
Hydropathy	
Polar	
Charge	
UniprotNLSRegion	69..76
UniprotNESRegion	285..292
SeqNLSRegion	
SeqNLSPMID	
nlsdbnes_region	
nlsdbnls_region	
validnes_region	
nesbase_region	
Sequence	MADPEVCCFITKILCAHGGRMALDALLQEIALSEPQLCEVLQVAGPDRFVVLETGGEAGITRSVVATTRARVCRRKYCQRPCDNLHLCKLNLLGRCNYSQSERNLCKYSHEVLSEENFKVLKNHELSGLNKEELAVLLLQSDPFFMPEICKSYKGEGRQQICNQQPPCSRLHICDHFTRGNCRFPNCLRSHNLMDRKVLAIMREHGLNPDVVQNIQDICNSKHMQKNPPGPRAPSSHRRNMAYRARSKSRDRFFQGSQEFLASASASAERSCTPSPDQISHRASLEDAPVDDLTRKFTYLGSQDRARPPSGSSKATDLGGTSQAGTSQRFLENGSQEDLLHGNPGSTYLASNSTSAPNWKSLTSWTNDQGARRKTVFSPTLPAARSSLGSLQTPEAVTTRKGTGLLSSDYRIINGKSGTQDIQPGPLFNNNADGVATDITSTRSLNYKSTSSGHREISSPRIQDAGPASRDVQATGRIADDADPRVALVNGKYKGKTLWASTFVHDIPNGSSQVVDKTTDVEKTGATGFGLTMAVKAEKDMLCTGSQSLRNLVPTTPGESTAPAQVSTLPQSPAALSSSNRAAVWGAQGQNCTQVPVSSASELTRKTTGSAQCKSLKDKGASVS
PTM	Acetylation:12,89,107,119,222,296,597,625,695,729,783,813,829;Methylation:107,119,179,360,374,385,544,557,625,770,849,882;Phosphorylation:77,127,221,235,247,249,257,263,265,271,273,275,280,284,294,298,299,302,310,312,321,322,326,327,335,346,347,348,351,355,361,364,375,378,380,386,387,390,393,398,403,407,408,410,419,444,449,450,451,452,458,459,469,492,494,498,502,509,590,631,635,636,637,640,642,675,690,709,740,750,765,826,872;Ubiquitylation:12,76,89,107,119,122,131,154,197,222,226,296,314,360,374,401,416,448,597,625,629,695,726,755,761,783,816,829
